Immunotherapy, particularly immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 or CTLA-4, has significantly improved cancer treatment outcomes (Wang et al., 2024). The gene discussed is CTLA4; the disease is cancer.